These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 12549858)

  • 1. A monoclonal antibody that blocks VEGF binding to VEGFR2 (KDR/Flk-1) inhibits vascular expression of Flk-1 and tumor growth in an orthotopic human breast cancer model.
    Zhang W; Ran S; Sambade M; Huang X; Thorpe PE
    Angiogenesis; 2002; 5(1-2):35-44. PubMed ID: 12549858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice.
    Brekken RA; Overholser JP; Stastny VA; Waltenberger J; Minna JD; Thorpe PE
    Cancer Res; 2000 Sep; 60(18):5117-24. PubMed ID: 11016638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of VEGF and its receptors Flt-1 and Flk-1/KDR is altered in lambs with increased pulmonary blood flow and pulmonary hypertension.
    Mata-Greenwood E; Meyrick B; Soifer SJ; Fineman JR; Black SM
    Am J Physiol Lung Cell Mol Physiol; 2003 Jul; 285(1):L222-31. PubMed ID: 12665467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular endothelial growth factor as a marker of tumor endothelium.
    Brekken RA; Huang X; King SW; Thorpe PE
    Cancer Res; 1998 May; 58(9):1952-9. PubMed ID: 9581838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective blockade of vascular endothelial growth factor receptor 2 with an antibody against tumor-derived vascular endothelial growth factor controls the growth of human pancreatic adenocarcinoma xenografts.
    Holloway SE; Beck AW; Shivakumar L; Shih J; Fleming JB; Brekken RA
    Ann Surg Oncol; 2006 Aug; 13(8):1145-55. PubMed ID: 16791450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vascular endothelial growth factor and vascular targeting of solid tumors.
    Brekken RA; Thorpe PE
    Anticancer Res; 2001; 21(6B):4221-9. PubMed ID: 11908675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts.
    Roland CL; Dineen SP; Lynn KD; Sullivan LA; Dellinger MT; Sadegh L; Sullivan JP; Shames DS; Brekken RA
    Mol Cancer Ther; 2009 Jul; 8(7):1761-71. PubMed ID: 19567820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Src kinase becomes preferentially associated with the VEGFR, KDR/Flk-1, following VEGF stimulation of vascular endothelial cells.
    Chou MT; Wang J; Fujita DJ
    BMC Biochem; 2002 Dec; 3():32. PubMed ID: 12509223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KDR/Flk-1 is a major regulator of vascular endothelial growth factor-induced tumor development and angiogenesis in murine hepatocellular carcinoma cells.
    Yoshiji H; Kuriyama S; Hicklin DJ; Huber J; Yoshii J; Miyamoto Y; Kawata M; Ikenaka Y; Nakatani T; Tsujinoue H; Fukui H
    Hepatology; 1999 Nov; 30(5):1179-86. PubMed ID: 10534339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vascular endothelial growth factor monoclonal antibody inhibits growth of anaplastic thyroid cancer xenografts in nude mice.
    Bauer AJ; Terrell R; Doniparthi NK; Patel A; Tuttle RM; Saji M; Ringel MD; Francis GL
    Thyroid; 2002 Nov; 12(11):953-61. PubMed ID: 12490072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin II regulation of vascular endothelial growth factor and receptors Flt-1 and KDR/Flk-1 in cyclosporine nephrotoxicity.
    Shihab FS; Bennett WM; Isaac J; Yi H; Andoh TF
    Kidney Int; 2002 Aug; 62(2):422-33. PubMed ID: 12110003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-VEGF-A therapy reduces lymphatic vessel density and expression of VEGFR-3 in an orthotopic breast tumor model.
    Whitehurst B; Flister MJ; Bagaitkar J; Volk L; Bivens CM; Pickett B; Castro-Rivera E; Brekken RA; Gerard RD; Ran S
    Int J Cancer; 2007 Nov; 121(10):2181-91. PubMed ID: 17597103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis.
    Warren RS; Yuan H; Matli MR; Gillett NA; Ferrara N
    J Clin Invest; 1995 Apr; 95(4):1789-97. PubMed ID: 7535799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-VEGF antibody in experimental hepatoblastoma: suppression of tumor growth and altered angiogenesis.
    McCrudden KW; Hopkins B; Frischer J; Novikov A; Huang J; Kadenhe A; New T; Yokoi A; Yamashiro DJ; Kandel JJ; Middlesworth W
    J Pediatr Surg; 2003 Mar; 38(3):308-14; discussion 308-14. PubMed ID: 12632340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. VEGF-VEGF receptor complexes as markers of tumor vascular endothelium.
    Brekken RA; Thorpe PE
    J Control Release; 2001 Jul; 74(1-3):173-81. PubMed ID: 11489493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Expression of vascular endothelial growth factor and its receptors in endometrial carcinoma].
    Wang H; Chen G; Zhang B
    Zhonghua Bing Li Xue Za Zhi; 2002 Oct; 31(5):391-5. PubMed ID: 12485477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Localization of vascular endothelial growth factor and its receptors in digestive endocrine tumors: correlation with microvessel density and clinicopathologic features.
    La Rosa S; Uccella S; Finzi G; Albarello L; Sessa F; Capella C
    Hum Pathol; 2003 Jan; 34(1):18-27. PubMed ID: 12605362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of vascular endothelial growth factor and its receptors KDR and Flt-1 in gastric cancer cells.
    Zhang H; Wu J; Meng L; Shou CC
    World J Gastroenterol; 2002 Dec; 8(6):994-8. PubMed ID: 12439912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VEGF-mediated angiogenesis of human pheochromocytomas is associated to malignancy and inhibited by anti-VEGF antibodies in experimental tumors.
    Zielke A; Middeke M; Hoffmann S; Colombo-Benkmann M; Barth P; Hassan I; Wunderlich A; Hofbauer LC; Duh QY
    Surgery; 2002 Dec; 132(6):1056-63; discussion 1063. PubMed ID: 12490855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.
    Petit AM; Rak J; Hung MC; Rockwell P; Goldstein N; Fendly B; Kerbel RS
    Am J Pathol; 1997 Dec; 151(6):1523-30. PubMed ID: 9403702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.